About Eucalyptus
Eucalyptus is a company based in Sydney (Australia) founded in 2018 by Charlie Gearside, Tim Doyle, and Benny Kleist was acquired by Hims in February 2026. It operates as a On-Demand Services, Subscription Services, and HealthTech. Eucalyptus has raised $67.34 million across 3 funding rounds from investors including Hims, BOND and Blackbird Ventures. Eucalyptus offers products and services including Kin, Pilot, Juniper, Compound, and Software. Eucalyptus operates in a competitive market with competitors including Amwell, Truepill, VSee, eVisit and Bright.md, among others.
- Headquarter Sydney, Australia
- Founders Charlie Gearside, Tim Doyle, Benny Kleist
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eucalyptus
-
Annual Revenue
$8.53 K (USD)-74as on Dec 31, 2023
-
Net Profit
-$1.4 K (USD)89as on Dec 31, 2023
-
EBITDA
Not available
-
Total Equity Funding
$67.34 M (USD)
in 3 rounds
-
Latest Funding Round
$42.92 M (USD), Series C
Jan 27, 2022
-
Investors
Hims
& 7 more
-
Employee Count
Not available
-
Acquired by
Hims
(Feb 19, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eucalyptus
Eucalyptus offers a comprehensive portfolio of products and services, including Kin, Pilot, Juniper, Compound, and Software.
Reproductive care is provided for women’s health needs.
Men’s health issues are addressed through telehealth services.
Weight loss solutions are offered for women globally.
Preventative health programs are designed for men’s longevity.
Custom skincare treatments are delivered via telehealth.
Funding Insights of Eucalyptus
Eucalyptus has successfully raised a total of $67.34M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $42.92 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Eucalyptus
Eucalyptus has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Hims, BOND and Blackbird Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in multiple sectors are made by Bond Capital.
|
Locked | Locked | Locked | |
|
Investments are made in seed, early, and later-stage tech companies.
|
Locked | Locked | Locked | |
|
Venture capital investment firm
|
Locked | Locked | Locked |
Investor details for Eucalyptus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eucalyptus
Investment portfolio details for Eucalyptus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Eucalyptus
Detailed financials for Eucalyptus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eucalyptus Comparisons
Peer comparison for Eucalyptus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eucalyptus
Eucalyptus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amwell, Truepill, VSee, eVisit and Bright.md, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Telehealth solutions are provided for doctors and patients' consultations.
|
|
| Locked | Locked | Locked |
Medicines are ordered and delivered through an API-connected healthcare app.
|
|
| Locked | Locked | Locked |
Secure video platforms for telehealth, education, and enterprises are provided.
|
|
| Locked | Locked | Locked |
A virtual care platform is provided for health systems by eVisit.
|
|
| Locked | Locked | Locked |
Provider of virtual telehealth and physician assistant for hospitals and patients
|
|
| Locked | Locked | Locked |
Form-based consultation software is provided for patients and healthcare providers.
|
Detailed competitors of Eucalyptus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eucalyptus
Complete news archive for Eucalyptus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eucalyptus
Eucalyptus was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Eucalyptus is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Tim Doyle is the current CEO of Eucalyptus. They have also founded this company.
Eucalyptus is a funded company, having raised a total of $67.34M across 3 funding rounds to date.
Annual revenue of Eucalyptus is $8.53K as on Dec 31, 2023.
Healthcare solutions are delivered by Eucalyptus through a network of digital clinics focusing on telehealth. Various sectors including reproductive health, mens health, womens weight management, preventative care, and skincare are covered. Clinics such as Kin, Pilot, Juniper, Compound, and Software are operated to provide accessible, safe, and effective medical consultations and treatments. Chronic conditions are treated, preventative care is emphasized, and outdated systems are evolved to ensure patients receive quality care. Operations span multiple countries including Australia, the UK, Germany, and Japan, ensuring a broad reach for patient-centered services.
Eucalyptus offers Kin, Pilot, Juniper, Compound, and Software.
Eucalyptus has 8 investors. Key investors include Hims, BOND, Blackbird Ventures, NewView Capital, and W23.